Myeloma

Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone.

The hope, according to an expert, is that this trial will expand CAR-T cell therapy access to more patients with multiple myeloma.

The combination of Sarclisa, Kyprolis and dexamethasone improved progression-free survival in patients with pretreated, relapsed myeloma, and has potential to become a new standard of care, an expert said.

They work as a team always. In this way, they are always up-to-date on each and every patient’s condition and needs.

As anyone who has sat at the bedside of a terminally ill patient knows, those who hold out a hand — literally or figuratively — to help a patient and their loved ones is a hero to them.

In recent years, BCMA-targeted therapies have changed the landscape of relapsed/refractory myeloma treatment, filling a previously unmet need.

The results, according to the study authors, may highlight a bigger issue related to structural racism in health care.

Watch Kristie L. Kahl, with Sham Mailankody, MBBS; Cesar Rodriguez, MD; and Lynn Steele, discuss new therapies on the horizon, during the CURE Educated Patient Multiple Myeloma Summit.

Here are some key takeaways from the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Cesar Rodriguez, of the Multiple Myeloma Program at the Ichan School of Medicine at Mount Sinai, discuss upcoming FDA approvals in the space, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Sham Mailankody, from Memorial Sloan Kettering Cancer Center, discuss CAR and BiTE therapy, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Saad Z. Usmani, Dr. Ben Marcus and Stan Wagner discuss their participation in the Moving Mountains for Multiple Myeloma program, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Kristie L. Kahl, Donna and Jack McNutt, Dr. Noopur Raje, and Grace Allison, discuss treating myeloma long term, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Saad Z. Usmani, Dr. Krina K. Patel, Dr. Noa Biran, and Jenny Ahlstrom, answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Noa Biran, an associate professor of medicine in the division of multiple myeloma at The John Theurer Cancer Center at Hackensack University Medical Center, discuss treatment for relapsed/refractory myeloma.

Watch Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center discuss treatment for newly diagnosed myeloma.

Watch Saad Z. Usmani, MD, MBA, with Carlyn Rose Tan, MD; Neha S. Korde, MD; and Kenny Capps answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Carlyn Rose Tan, an assistant attending in myeloma service at Memorial Sloan Kettering Cancer Center, present on risk stratification for newly diagnosed patients.

Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma.

To address symptoms from myeloma that is resistant to treatment, education and communication with care teams are key.

Bone pain is a common symptom that patients with multiple myeloma face, but some may find relief with treatments and exercise.

One of the hurdles, according to the study’s lead author, is that many patients with cancer are worried about receiving a placebo in a clinical trial.

In honor of CURE®’s 20th anniversary, we spoke with experts on how the past 20 years have revolutionized multiple myeloma treatment.

Many things can influence a patient’s response to the COVID-19 vaccine, such as their treatments or whether they have a higher tumor burden.

It can be difficult for patients to go about their daily life with this bone pain, so what can help?

As part of its “Speaking Out” video series, CURE® spoke with Throwing Bones founder Kenny Capps about the importance of patient-physician communication during a myeloma journey.

Donna McNutt uses her love of fashion to find confidence and motivation — and shares it with others — after a myeloma diagnosis.

When cancer harms the body’s ability to make antibodies, what does that mean for the efficacy of vaccines?

Durable and deep responses occurred in patients with multiple myeloma after use of a particular CAR-T cell therapy

As more and more people in their 20s and 30s begin to receive diagnoses of multiple myeloma, a type of blood cancer, one expert stresses that continued research to improve survival in this patient population is critical.